Strontium Ranelate Reduces Duration of Consolidation Phase in Distraction Osteogenesis: 2 Case Reports

Kishan Rao Subramaniam1, Ed Simor Khan1, Ahmad Hafiz Zulkifly1 and Ashwini Sood2

1Department of Orthopedic, International Islamic University Malaysia, Malaysia
2Department of Orthopedic, Hospital Kulim Kedah, Malaysia

*Corresponding author: Kishan Rao Subramaniam, Department of Orthopedic, Malaysia

Submission: July 05, 2017; Published: July 16, 2018

Abstract

Distraction osteogenesis a debilitating and time consuming procedure in orthopedics. The common indications for distraction osteogenesis are open fractures, non union and bone resection due to chronic osteomyelitis or large bone loss at initial time of trauma. It is often a limb salvage procedure but also has a role in cosmetic lengthening in short statures. In distraction osteogenesis, there are 3 main phases; latent phase, distraction phase and consolidation phase. Often, patient has to be on external fixator (eg: ilizarov, LRS) for the entire duration of the distraction osteogenesis until clinical union is achieved (frame time). Prolonged external fixation is uncomfortable for the patient and is associated with many complications. Strontium ranelate is widely used in treatment of osteoporosis and to prevent fractures in elderly population. It has dual action and it promotes osteoblastic activity and inhibits osteoclastic activities in bone cells. From our cases, we have found that strontium ranelate given to patients at the end of distraction phase of distraction osteogenesis have significantly reduced the duration of consolidation phase, thus shortening the duration of the patients on external fixator (frame time). Strontium ranelate is a cost effective and non invasive alternative and can be used to reduce patients’ suffering, improve patients’ compliance and reduce the disability period. However, further evaluation of the safety profile of the drug needs to be taken into consideration.

Keywords: Distraction osteogenesis; Bone transport; Frame time; Strontium ranelate; Consolidation phase

Introduction

Distraction osteogenesis was invented by Gavriil Abramovich Ilizarov from Russia in 1951 [1]. Distraction osteogenesis is a debilitating and time consuming procedure in orthopedics. The common indications for distraction osteogenesis are open fractures, non-union, bone resection due to chronic osteomyelitis or large bone loss at initial time of trauma [1-8]. It is often a limb salvage procedure but also has a role in cosmetic lengthening in short statures [3,9]. Other known methods to treat large bone deficiencies are bone grafting (autograft, allograft or synthetic), membrane induction technique or also known as Masquelet technique, cortical strut grafting, or vascularised bone grafting [1,3,8-10]. Some literatures also have mentioned acute shortening of the fracture ends and bone lengthening later [7]. In bone transport, there are 3 main phases; latent phase, distraction phase and consolidation phase [3,9]. Patient has to be on external fixator (eg: ilizarov, LRS) for the entire duration of the bone transport until clinical union is achieved. Prolonged external fixation is uncomfortable for the patient and is associated with many complications such as pin site infections, pin dislodgement, mal-union, mechanical failure and poor cosmetic appearance [1,8,9]. It is the main reason for lack of compliance from patients, which is a significant setback for this otherwise a revolutionary procedure in orthopedics.

Strontium ranelate is used in treatment of osteoporosis. It has dual action; stimulates osteoblastic activity and inhibits osteoclastic activity [9,11-15]. It is widely used in treatment of osteoporosis and to prevent fractures in elderly population. From our cases, we have found that strontium ranelate given to patients at the end of distraction phase have significantly reduced the duration of consolidation phase of the regenerated part in these patients. Thus, reducing the duration the patients have to be on external fixator (frame time).

Case Report

Patient 1

19 years old boy sustained open fracture grade 3A of right distal 3rd femur, done wound debridement+interlocking nailing of femur. Unfortunately, 5 months later patient presented with chronic osteomyelitis. 8.5cm of bone was removed. Later, bone transport was started using LRS system. Bone transport was completed 3 months (87 days) later and bone grafting+plating was done at...
docking site. Patient was thereafter started on Strontium Ranelate 2g/od. Below are the x-rays of the patient. It shows that the new bone formed has consolidated well and docking site has united. LRS was removed earlier than the expected duration and patient is ambulating FWBA with single crutches (Figure 1).

![Post-corticotomy, Docking, 6 weeks post Strontium, 14 weeks post strontium. Bone consolidated. LRS removed](image)

**Figure 1:**  
Total length transported=8.5cm  
Total duration of transport (0.5mm BD)=87 days  
Expected duration of consolidation phase=87x2=174 days  
Expected total duration patient on LRS (transport+consolidation)=261 days  
Total duration of consolidation phase after strontium=98 days  
Total=185 days (Save 76 days).

**Patient 2**

17 years old boy sustained open fracture grade 3A of right femur. However, patient opted for traditional treatment and came back 1 year later with malunited femur with 7cm gross shortening and pus discharging sinus over the medial aspect of thigh. Working diagnosis was malunited femur with gross shortening and chronic osteomyelitis. Routine treatment was done, followed by gradual correction of deformity (rotation) and lengthening by Taylors Spatial Frame. Total duration of correction+lengthening was 72 days. After achieving the desired length, patient was started on strontium 2g OD to enhance bone consolidation. Below are the x-rays of the patient.

In both our cases, the patients were started on strontium ranelate 2g/day at the end of distraction phase and were continued throughout the consolidation phase until clinical union was achieved. The quality of regenerate bone on radiographs was
normal. The end point for removal of external fixator was based on clinical union and radiological consolidation which was assessed by our senior orthopedic consultant. Both the patients were followed up for a minimum of 1 year and no complications were noted during the follow up period (Figure 2).

**Discussion**

Distraction osteogenesis is a surgical technique by which bone regeneration is induced between surgically osteotomized bone segments that undergo gradual distraction resulting in bone lengthening [4]. Codivilla was the first to explore distraction osteogenesis, and in 1904 reported applying this technique for lengthening of the lower limbs [1]. However, it was not until 1950 that this technique widespread through the works of Ilizarov. The common indications for distraction osteogenesis are open fractures, bone resection due to chronic osteomyelitis or infected non-union, large bone loss at initial time of trauma, limb length discrepancies and bony deformities [1-7,16]. It is often a limb salvage procedure but also has a role in cosmetic lengthening in short statures [2,9]. In distraction osteogenesis, bone heals by primary bone healing [17]. It results in new bone formation through the lengthening of the bone callus (also known ascallotasis). Induced traction generates tension within the callus and stimulates the formation of new bone parallel to the distraction vector. This force also creates tension on the surrounding soft tissues, initiating a sequence of adaptive changes known as distraction histogenesis [3]. Up to 10% lengthening is well-tolerated by muscle, but substantial histopathological changes occur after lengthening of 30% [1]. The gold standard for bone defect repairs is autograft but their usage is affected by morbidity at the donor site and limited supply. Limitations of the allograft include the immunogenic response by the host to the graft and the potential for disease transmission. Distraction osteogenesis can eliminate the need for bone grafts. Other known methods to treat large bone deficiencies are allografts, synthetic bone grafts, membrane induction technique or also known as Masquelet technique, cortical strut grafting, or vascularised bone grafting [2-6,8,9]. Some literatures also have mentioned acute shortening followed by bone lengthening later [7].

![Figure 2](image_url)

**Figure 2:**
- Total length corrected=7.0cm
- Total duration of lengthening=72 days
- Expected duration of consolidation phase=72 x 2=144 days
- Expected total duration patient on TSF (lengthening+ consolidation)=216 days
- Total duration of consolidation after strontium=91 days
- Total=163 (Save 53 days).
interzone comprising of type I collagen. New bone trabeculae form directly from this central collagen zone extending to both bone surfaces. However, the rate can vary depending on the quality of the regenerate bone. Consolidation phase is the end of distraction to bony unionor consolidation of the regenerate bone. It can be of 3 qualities: normal, hypertrophic of hypotrophic [8].

Up until now, the decision to discontinue distraction has been based more on personal experience than on objective data. None of the radiologic method used in assessing consolidation phase has given encouraging qualitative or quantitative results. However, a clinical study using scintography Tc-99 DP has shown good results in determining end of consolidation phase.

Consolidation was considered to be reached when no more further changes in tracer uptake at the regenerate bone compared with surrounding normal growing bone [18]. As a general rule, the duration of consolidation phase is usually twice the duration of distraction phase [10]. One of the limitations of distraction osteogenesis is the long period of time required for the newly formed bone tissue to mineralize and consolidate. For example, if the bone deficiency is 10cm, the duration of distraction phase is 100 days (0.25mm/day) and the duration of consolidation is 200 days, which is a total of 300 days. During this whole period, patient has to be on an external fixator (Ilizarov rings or LRS). This period is known as ‘frame time’ [5]. Prolonged external fixation is uncomfortable for the patient and is associated with many complications such as pin site infections, hardware failure, mal-union, soft tissue contractures and poor cosmetic appearance [2-4,6,9,16]. Many methods have been introduced to decrease frame time; these include converting external fixator to internal fixator. Such examples are lengthening over a nail, lengthening with submuscular plating and lengthening by implantable device [5,6]. On the other hand, there are also methods been introduced to accelerate bone consolidation of the regenerated segment in bone transport, such as low intensity ultrasound therapy, BMP-2 injection, platelet rich plasma (PRP) injection, growth hormones, autografting and reaming through the new bone [3,8,9]. Unfortunately, these methods are invasive, not cost effective and are associated with high risk of deep infections.

Recently, usages of certain anti osteoporotic drugs have surfaced to promote bone healing. Many animal studies have demonstrated that these drugs can positively influence fracture repair and implant osseointegration [12,15]. Such examples of drugs are teraparatide (PTH), strontium ranelate, bisphosphonates and calcium supplements. In both our cases, we have used strontium ranelate. Strontium ranelate is a strontium slat in ranelic acid. Strontium ranelate is a cost effective and non-invasive alternative to reducing the duration of frame time in a patient undergoing distraction osteogenesis. Thus, it can be used to reduce patients’ suffering, improve patients’ compliance and reduce the disability period of a patient. However, further evaluation of the safety profile of the drug needs to be taken into consideration.

Conclusion

Strontium ranelate is a cost effective and non-invasive alternative to reducing the duration of frame time in a patient undergoing distraction osteogenesis. Thus, it can be used to reduce patients’ suffering, improve patients’ compliance and reduce the disability period of a patient. However, further evaluation of the safety profile of the drug needs to be taken into consideration.

References